Ann: Company Update - Phase 1 Study Independent Review, page-2

Hello all - we have some important news and encourage everyone to visit our website for additional information.

We announced that a recent independent review of our imaging data was positive and we are now setting a priority path to market for our MagSense imaging agent technology.

• Blinded review by expert panel of radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance Imaging (MRI).
• We are now prioritizing the development of our pipeline of tumour targeting MagSense® imaging agents for use with widely available commercial MRI systems as a faster path to patients and the market.

We will also be hosting a live webinar on 7 Feb @ 12pm AEDT to provide additional details and answer questions. We hope you join us!

Learn more: https://imagionbiosystems.com/news/priority-path-to-market-for-magsense-technology/